Genomic Risk Classifiers in Prostate Cancer: Precise Tools Awaiting Clinical Standardization
GRCs for prostate cancer show promise but lack standardization, with usage patterns varying by income and geography in clinical practice.
September 12, 2025
Rare but Targetable: EGFR Mutations Identified in 0.08% of Ovarian Cancers
EGFR mutations found in 0.08% of ovarian cancers; one patient achieved 17+ month response to osimertinib.
Rare but Targetable: EGFR Mutations Identified in 0.08% of Ovarian Cancers Read More »
FDA Approves Gemcitabine Intravesical System (Inlexzo) for BCG-Unresponsive Bladder Cancer
FDA approves gemcitabine intravesical system for BCG-unresponsive bladder cancer, showing 82% complete response rate in SunRISe-1 trial.
GammaTile Brachytherapy Demonstrates Superior Local Control in Recurrent Brain Metastases
GammaTile achieved 87% local control at 1 year in recurrent brain metastases with 8% toxicity, outperforming historical controls.
From ‘Undruggable’ to Breakthrough: Pan-RAS Inhibitors Transform GI Oncology Practice
Pan-RAS inhibitors like RMC-6236 are showing unprecedented 30% response rates in previously treated pancreatic cancer, potentially ending the decades-long frustration of targeting “undruggable” KRAS mutations. Meanwhile, durvalumab plus FLOT (D-FLOT) and zolbetuximab are reshaping treatment paradigms in gastroesophageal cancers with improved survival outcomes. Expert Commentary Scope & Focus Key Clinical Developments Pan-RAS Inhibitors in Pancreatic
From ‘Undruggable’ to Breakthrough: Pan-RAS Inhibitors Transform GI Oncology Practice Read More »
EMPOWER-Lung 1: Cemiplimab Shows Sustained 5-Year Survival Benefit in Advanced NSCLC
Five-year OS probability was 29.0% for cemiplimab and 15.0% for chemotherapy in advanced NSCLC patients with ≥50% PD-L1 expression.
EMPOWER-Lung 1: Cemiplimab Shows Sustained 5-Year Survival Benefit in Advanced NSCLC Read More »
GLP-1 Receptor Agonists Show Multi-Modal Anticancer Potential in Early Research
GLP-1s could impact cancer patients through weight loss, immune modulation, and chemotherapy resistance mechanisms, though standalone treatment remains distant.
GLP-1 Receptor Agonists Show Multi-Modal Anticancer Potential in Early Research Read More »